Ilyang Pharm (KO:007570) — Stock Price
Ilyang Pharm (KO:007570) is currently trading at ₩8700.00 KRW, up 2.35% today. Over the past 52 weeks, shares have ranged between ₩7860.00 and ₩13160.00. This page tracks Ilyang Pharm's live share price on the KO exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see Ilyang Pharm (007570) total market value.
Ilyang Pharm (007570) Stock Price Chart — Daily History & Trading Volume
The chart below tracks Ilyang Pharm's daily closing share price and trading volume on the KO exchange over the past year, giving a clear view of recent price momentum and liquidity.
Ilyang Pharm Income Statement — Revenue, Profit & Earnings by Year
Ilyang Pharm's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | ₩268.86 Billion | ₩266.67 Billion | ₩383.81 Billion | ₩371.35 Billion | ₩343.33 Billion |
| Cost of Revenue | ₩157.39 Billion | ₩150.18 Billion | ₩167.78 Billion | ₩166.94 Billion | ₩161.62 Billion |
| Gross Profit | ₩111.48 Billion | ₩116.49 Billion | ₩216.03 Billion | ₩204.40 Billion | ₩181.71 Billion |
| Research & Development | ₩24.74 Billion | ₩23.75 Billion | ₩25.96 Billion | ₩20.20 Billion | ₩19.72 Billion |
| SG&A | ₩23.94 Billion | ₩23.95 Billion | ₩96.56 Billion | ₩89.80 Billion | ₩82.46 Billion |
| Total Operating Expenses | ₩257.86 Billion | ₩250.29 Billion | ₩343.40 Billion | ₩330.32 Billion | ₩309.23 Billion |
| Operating Income | ₩11.00 Billion | ₩16.38 Billion | ₩40.41 Billion | ₩41.03 Billion | ₩34.10 Billion |
| EBITDA | — | — | ₩56.85 Billion | ₩53.64 Billion | ₩44.07 Billion |
| EBIT | — | — | ₩40.41 Billion | ₩41.03 Billion | ₩34.10 Billion |
| Interest Expense | ₩2.93 Billion | ₩3.23 Billion | ₩2.46 Billion | ₩2.06 Billion | ₩3.02 Billion |
| Income Before Tax | ₩12.28 Billion | ₩-1.80 Billion | ₩41.33 Billion | ₩38.93 Billion | ₩28.39 Billion |
| Income Tax Expense | — | — | ₩9.59 Billion | ₩12.97 Billion | ₩6.85 Billion |
| Net Income | ₩10.26 Billion | ₩-2.41 Billion | ₩19.24 Billion | ₩14.38 Billion | ₩10.88 Billion |
Ilyang Pharm Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes Ilyang Pharm's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Assets | ₩431.21 Billion | ₩356.66 Billion | ₩498.19 Billion | ₩494.27 Billion | ₩439.12 Billion |
| Total Current Assets | ₩125.37 Billion | ₩114.20 Billion | ₩200.73 Billion | ₩203.56 Billion | ₩162.50 Billion |
| Cash & Equivalents | — | — | — | — | — |
| Short-term Investments | ₩8.49 Billion | ₩6.78 Billion | ₩5.42 Billion | ₩34.34 Billion | ₩270.87 Million |
| Net Receivables | ₩44.96 Billion | ₩46.47 Billion | ₩60.15 Billion | ₩63.16 Billion | ₩58.68 Billion |
| Inventory | ₩59.87 Billion | ₩51.78 Billion | ₩61.37 Billion | ₩41.19 Billion | ₩48.59 Billion |
| Property, Plant & Equipment | — | — | ₩199.12 Billion | ₩198.31 Billion | ₩185.97 Billion |
| Goodwill | — | — | — | — | — |
| Total Liabilities | ₩189.63 Billion | ₩160.25 Billion | ₩206.33 Billion | ₩222.51 Billion | ₩194.19 Billion |
| Total Current Liabilities | ₩156.90 Billion | ₩139.19 Billion | ₩186.86 Billion | ₩198.21 Billion | ₩177.15 Billion |
| Long-term Debt | ₩14.70 Billion | ₩6.00 Billion | — | ₩5.02 Billion | — |
| Net Debt | ₩102.91 Billion | ₩71.71 Billion | ₩25.02 Billion | ₩53.35 Billion | ₩61.40 Billion |
| Total Stockholder Equity | ₩237.99 Billion | ₩196.41 Billion | ₩234.65 Billion | ₩224.11 Billion | ₩207.19 Billion |
| Retained Earnings | ₩61.10 Billion | ₩25.55 Billion | ₩58.99 Billion | ₩43.55 Billion | ₩31.41 Billion |
Ilyang Pharm Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how Ilyang Pharm generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₩5.61 Billion | ₩13.34 Billion | ₩29.94 Billion | ₩67.02 Billion | ₩57.48 Billion |
| Capital Expenditures | ₩40.62 Billion | ₩6.47 Billion | ₩4.08 Billion | ₩12.91 Billion | ₩10.17 Billion |
| Free Cash Flow | ₩-35.01 Billion | ₩6.87 Billion | ₩9.40 Billion | ₩45.67 Billion | ₩32.86 Billion |
| Investing Cash Flow | — | — | ₩7.59 Billion | ₩-21.34 Billion | ₩-21.16 Billion |
| Financing Cash Flow | — | — | ₩-23.40 Billion | ₩-43.13 Billion | ₩-30.96 Billion |
| Dividends Paid | ₩2.97 Billion | ₩2.79 Billion | ₩3.94 Billion | ₩8.77 Billion | ₩4.90 Billion |
| Stock-Based Compensation | — | — | — | — | — |
| Depreciation | ₩9.82 Billion | ₩10.60 Billion | ₩13.06 Billion | ₩12.65 Billion | ₩12.66 Billion |
| Change in Cash | ₩881.17 Million | ₩-3.60 Billion | ₩11.87 Billion | ₩6.39 Billion | ₩5.45 Billion |
Ilyang Pharm Earnings History — EPS Actual vs. Analyst Estimates
Track Ilyang Pharm's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| May 13, 2026 | — | — | — |
| Jan 30, 2026 | — | — | — |
| Nov 12, 2025 | — | — | — |
| Aug 12, 2025 | 31.38 | — | — |
| May 15, 2025 | 190.99 | — | — |
| Jan 31, 2025 | 205.10 | — | — |
| Nov 12, 2024 | 192.15 | — | — |
| Aug 14, 2024 | 60.42 | — | — |